Please check out our latest poster (#708) presenting clinical study results of a head-to-head comparison between Levodopa Cyclops® and Inbrija®.
Highlights are:
- Levodopa Cyclops® is safe and very well tolerated (no cough).
- Levodopa absorption from Cyclops® is comparable to Inbrija®, thereby, fulfilling the bioequivalence criteria.
- Results enable abbreviated registration routes with a limited – PK-only – clinical program.
- Levodopa Cyclops® is very easy to use and systemic absorption is fast, so it will be a valuable asset to offer fast and reliable relief of debilitating OFF episodes.
This poster will be presented by Jaap Wieling (CEO) during the ‘International Congress of Parkinson’s Disease and Movement Disorders’ in Philadelphia on Sunday the 29th of September 2024 (Exhibit Hall A).
Click on the image for a pdf copy of the poster.
